CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
729.70MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.0890xvs all stocks
52-Week Change
242.81%vs all stocks
Market Capitalization
729.70MUSDvs all stocks (USD)
Enterprise Value
483.41MUSDvs all stocks (USD)
Forward P/E
-13.56xvs Biotechnology peers
Price to Book (MRQ)
6.32xvs Biotechnology peers
Enterprise to EBITDA
-13.51xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-38.97%vs Biotechnology peers
Return on Equity (TTM)
-74.46%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-35.78MUSDvs all stocks (USD)
Net Income (TTM)
-34.98MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-32.07MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-20.32MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
0.00USDFY2025 · Dec 31, 2025Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-29.96MUSDvs all stocks (USD)
Pre-tax Income
-29.40MUSDFY2025 · Dec 31, 2025Income Tax Expense
37.72KUSDFY2025 · Dec 31, 2025Net Income
-29.44MUSDFY2025 · Dec 31, 2025EBIT
-29.96MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-29.59MUSDFY2025 · Dec 31, 2025Research & Development
16.26MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
13.70MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
555.53KUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-29.44MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
0.00USDFY2025 · Dec 31, 2025Operating Cash Flow
-23.64MUSDFY2025 · Dec 31, 2025Free Cash Flow
-24.38MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
93.93MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-29.44MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
364.50KUSDFY2025 · Dec 31, 2025Stock-based Compensation
2.44MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
2.06MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
1.03MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-98.01KUSDFY2025 · Dec 31, 2025Capital Expenditures
-732.92KUSDFY2025 · Dec 31, 2025Purchase of Investments
-6.48MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-7.21MUSDFY2025 · Dec 31, 2025Other Financing Charges
-137.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
107.26MUSDFY2025 · Dec 31, 2025Shares Outstanding
53.01MSharesUpdated Jul 19, 2026Float Shares
43.40MSharesUpdated Jul 19, 2026Shares Short
7.88MSharesUpdated Jul 19, 2026Short Ratio
3.90daysvs all stocks
Short % of Shares Outstanding
13.39%vs all stocks
% Held by Insiders
17.56%vs all stocks
% Held by Institutions
45.30%vs all stocks
Total Cash (MRQ)
90.58MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.67USDUpdated Jul 19, 2026Total Debt (MRQ)
1.04MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0123xvs Biotechnology peers
Current Ratio (MRQ)
8.76xvs Biotechnology peers
Book Value per Share (MRQ)
1.59USDUpdated Jul 19, 2026Total Assets
104.84MUSDvs all stocks (USD)
Total Current Assets
101.24MUSDFY2025 · Dec 31, 2025Total Liabilities
11.04MUSDFY2025 · Dec 31, 2025Total Non-current Assets
3.60MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
933.63KUSDFY2025 · Dec 31, 2025Total Current Liabilities
10.11MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
93.93MUSDFY2025 · Dec 31, 2025Other Short-term Investments
6.48MUSDFY2025 · Dec 31, 2025Accounts Payable
5.44MUSDFY2025 · Dec 31, 2025Short-term Debt
139.34KUSDFY2025 · Dec 31, 2025Long-term Debt
933.63KUSDFY2025 · Dec 31, 2025Common Stock (Book)
5.30KUSDFY2025 · Dec 31, 2025Retained Earnings
-104.46MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
93.80MUSDvs all stocks (USD)
Treasury Stock
99.96KUSDFY2025 · Dec 31, 202552-Week Low
1.94USDUpdated Jul 19, 202652-Week High
12.14USDUpdated Jul 19, 202652-Week Change
242.81%vs all stocks
Beta
0.0890xvs all stocks
50-Day MA
9.50USDUpdated Jul 19, 2026200-Day MA
7.00USDUpdated Jul 19, 2026Avg 10-Day Volume
1.80MSharesUpdated Jul 19, 2026Avg 30-Day Volume
2.00MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.9200USDUpdated Jul 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.60
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Guangdong Biolight Meditech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
SS Innovations International, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Senores Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Getein Biotech Inc.
Tier 1ProductionApproval-Gated PipelineRule
Climb Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Yabao Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oculis Holding AG
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Sanyou Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aura Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhuzhou Qianjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Hebei Sinopack Electronic Co., Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Bloom Energy Corporation Class A
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Alto Neuroscience Inc.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets